12/08/2017 04:56:00

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Avinger, Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR) for possible violations of federal securities laws. Investors who purchased or otherwise acquired Avinger shares pursuant and/or traceable to its initial public offering (“IPO”) on January 30, 2015, should contact the firm prior to the September 5, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, the Registration Statement and Prospectus filed for Avinger’s IPO contained materially false and misleading statements and/or failed to disclose: that the Company did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; that Avinger already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; that physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement its lumivascular platform products instead of competing products and procedures available in the market; that the Company would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and that as a result of the above, Avinger was experiencing lower sales and revenues. Following this news, the Company’s shares fell in value, causing investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Oct
VWS
Der er for tiden en del debat omkring øget prispres på vindmøllemarkedet - bl.a. som følge af at Sie..
78
20 Oct
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker min analyse af Pandoras forretningsm..
59
18 Oct
EI
Til direktionen.     Se så at få fyret den uduelige person, som I har ansat som moderator. Vedkommen..
43
18 Oct
NOVO-B
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee votes 16 - 0 in favor of approval fo..
21
20 Oct
TEVA
Jeg deler spekulationerne omkring Kåres tiltrædelse dvs. den dårlige nyhedsstrøm er snart slut. Min ..
19
18 Oct
EI
Og til Moderator:     Du UNDERSTÅR dig i at fjerne dette indlæg uden at have forelagt det direktione..
17
18 Oct
PNDORA
Markedsværdi = DKK 64 milliarder   Pandora ejer 2,30 % af aktierne (som vi må antage ikke kommer i o..
14
16 Oct
OMXC25
Jeg har fuldstændig mistet enhver form for respekt for EU.   EU er i den grad blevet til en taberfor..
14
20 Oct
PNDORA
lugte af noget personligt mod alfinvest, vil jeg nu tillade mig at drage tvivl, både ved hans hensig..
13
20 Oct
PNDORA
Vanvittigt godt formuleret Peter. Det er næsten som at tage på universitetet og studere grønlandsk a..
13

Alliance Trust PLC : Net Asset Value(s)

23/10/2017 13:14:06
ALLIANCE TRUST PLC                                    At the close of business on Friday 20 October 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.5p -       including income, 787.1p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inco..

Rathbones : Form 8.3 - [Clinigen Group PLC]

23/10/2017 10:58:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Rathbone Brothers PLC (b) Owner or controller of ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
H.B. Fuller Poised for Global Growth with Acquisition of Royal Adhesives & Sealants
2
Sequent Announces Two New Sequent Platform Versions
3
Simmons Reports Third Quarter 2017 Earnings
4
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
5
MEDIA ADVISORY: US Commerce Secretary Wilbur Ross to Hold Listening Session at National Minority Supplier Development Council Annual Conference

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 October 2017 18:07:47
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171023.1 - EUROWEB7 - 2017-10-23 19:07:47 - 2017-10-23 18:07:47 - 1000 - Website: OKAY